Achieve Life Sciences Inc (F:SP4P) — Market Cap & Net Worth
Market Cap & Net Worth: Achieve Life Sciences Inc (SP4P)
Achieve Life Sciences Inc (F:SP4P) has a market capitalization of $480.44 Million (€410.95 Million) as of August 16, 2026. Listed on the F stock exchange, this Germany-based company holds position #12485 globally and #1338 in its home market, demonstrating a 8.77% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Achieve Life Sciences Inc's stock price €6.20 by its total outstanding shares 102659057 (102.66 Million). See how leveraged is Achieve Life Sciences Inc's balance sheet to understand what proportion of total assets are financed by equity.
Achieve Life Sciences Inc Market Cap History: 2015 to 2026
Achieve Life Sciences Inc's market capitalization history from 2015 to 2026. Data shows change from $279.62 Billion to $744.12 Million (-45.62% CAGR). Also see Achieve Life Sciences Inc (SP4P) total assets for a full breakdown of the balance sheet.
Achieve Life Sciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Achieve Life Sciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check SP4P stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
26289.47x
Achieve Life Sciences Inc's market cap is 26289.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $133.08 Billion | $5.06 Million | -$20.13 Million | 26289.47x | N/A |
Competitor Companies of SP4P by Market Capitalization
Companies near Achieve Life Sciences Inc in the global market cap rankings as of August 16, 2026. Also see SP4P cash flow metrics for how efficiently the company converts equity into cash flow.
Key companies related to Achieve Life Sciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #431 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #545 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #557 globally with a market cap of $48.56 Billion USD ( ₩71.66 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $505.75 |
| #431 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $803.48 |
| #545 | Argen-X | BR:ARGX | $49.55 Billion | €730.20 |
| #557 | Samsung Biologics Co Ltd | KO:207940 | $48.56 Billion | ₩1548000.00 |
Achieve Life Sciences Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Achieve Life Sciences Inc's market cap moved from $279.62 Billion to $ 744.12 Million, with a yearly change of -45.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €744.12 Million | +67.57% |
| 2025 | €444.07 Million | +3.79% |
| 2024 | €427.87 Million | -3.65% |
| 2023 | €444.07 Million | +57.31% |
| 2022 | €282.29 Million | -64.36% |
| 2021 | €792.13 Million | +4.76% |
| 2020 | €756.12 Million | -36.99% |
| 2019 | €1.20 Billion | -51.47% |
| 2018 | €2.47 Billion | -92.23% |
| 2017 | €31.83 Billion | -76.08% |
| 2016 | €133.08 Billion | -52.41% |
| 2015 | €279.62 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 15th, 2026 the market cap of Achieve Life Sciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $480.44 Million USD |
| MoneyControl | $480.44 Million USD |
| MarketWatch | $480.44 Million USD |
| marketcap.company | $480.44 Million USD |
| Reuters | $480.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreement… Read more